obesity drug news today glp-1 oct 27 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 Agonists Weight Loss Drugs

Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

Mohammed Ali, Dr

In summary, GLP-1 drugs offer significant advantages for individuals with type 2 diabetes or weight management concerns

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks